– KLF9 is significantly upregulated by intermittent hypoxia (IH) and plays a pivotal role in driving metabolic dysfunction-associated steatotic liver disease (MASLD).
– KLF9 suppresses transcription of the nuclear receptor NR4A1, inhibiting downstream activation of p38 MAPK signaling, which is crucial for maintaining hepatic metabolic balance.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
